Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel

Archives of Toxicology

Volumn 88, Issue 4, 2014, Pages 953-966

  Ter Braak, B ^a   Siezen, C L E ^c   Kannegieter, N ^a   Koedoot, E ^a   Van De Water, B ^a   Van Der Laan, J W ^a,b,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c MEDICINES EVALUATION BOARD   (Netherlands)

Author keywords

Human breast cancer; IGF1R; Insulin glargine; Mitogenic

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PIG INSULIN; PROTEIN KINASE B; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; X 10; ANTIDIABETIC AGENT; IGF1R PROTEIN, HUMAN; INSR PROTEIN, HUMAN; INSULIN; INSULIN, ASP(B10)-; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL STRAIN MCF 7; CLASSIFICATION; CONTROLLED STUDY; DRUG METABOLISM; EXPERIMENTAL MODEL; FEMALE; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MAMMARY GLAND; METABOLITE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TOXICOKINETICS; AGONISTS; ANALOGS AND DERIVATIVES; BIOTRANSFORMATION; BREAST TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; GENETIC TRANSFECTION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TIME FACTOR;

ANTIGENS, CD; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENETIC ENGINEERING; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, INSULIN; RECEPTORS, SOMATOMEDIN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84897108705     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1201-2     Document Type: Article

References (47)

1. Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33:205-212 (Pubitemid 46863409)
2. Andersson C, Vaag A, Selmer C, Schmiegelow M, Sorensen R, Lindhardsen J, et al (2012) Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2
3. Bahr M, Kolter T, Seipke G, Eckel J (1997) Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells. Eur J Pharmacol 320:259-265 (Pubitemid 27076754)
4. Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18:R125-R147
5. Bolli GB, Hahn AD, Schmidt R, Eisenblaetter T, Dahmen R, Heise T et al (2012) Plasma exposure to insulin glargine and its metabolites m1 and m2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care 35:2626-2630
6. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333:679-682
7. Chisalita SI, Arnqvist HJ (2004) Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 286:E896-E901 (Pubitemid 38668810)
8. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry R (2001) Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86:5838-5847 (Pubitemid 33152632)
9. Colhoun HM (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765
10. Currie CJ, Poole CD, Gale EA (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
11. Dideriksen LHJL, Drejer K (1992) Carcinogenic effect on female rats after 12 months administration of the insulin analogue B10 Asp. Diabetes 41
12. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19:608-624 (Pubitemid 28467714)
13. Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50:2534-2543 (Pubitemid 350060636)
14. Erbel S, Reers C, Eckstein VW, Kleeff J, Buchler MW, Nawroth PP et al (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31:1105-1111
15. Fawcett J, Tsui BT, Kruer MC, Duckworth WC (2004) Reduced action of insulin glargine on protein and lipid metabolism: possible relationship to cellular hormone metabolism. Metabolism 53:1037-1044 (Pubitemid 38988290)
16. Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319-328
17. Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732-1744
18. Hudelist G, Wagner T, Rosner M, Fink-Retter A, Gschwantler-Kaulich D, Czerwenka K et al (2007) Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer 14:1053-1062 (Pubitemid 351252436)
19. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
20. Kohn WD, Micanovic R, Myers SL, Vick AM, Kahl SD, Zhang L et al (2007) pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity. Peptides 28:935-948 (Pubitemid 46349342)
21. Kostev K (2012) Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin. Diabetologia 55:1554-1555
22. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005 (Pubitemid 30349423)
23. Liefvendahl E, Arnqvist HJ (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40:369-374 (Pubitemid 351967126)
24. Liu S, Li Y, Lin T, Fan X, Liang Y, Heemann U (2011) High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3 K-independent activation of Akt. Diabetes Res Clin Pract 91:177-182
25. Liu SY, Liang Y, Lin TX, Su F, Liang WW, Uwe H et al (2012) MEK1 and MEK2 differentially regulate human insulin- and insulin glargine-induced human bladder cancer T24 cell proliferation. Chin Med J (Engl) 125:4197-4201
26. Lucidi P, Porcellati F, Rossetti P, Candeloro P, Andreoli AM, Cioli P et al (2012) Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. Diabetes Care 35:2647-2649
27. Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33:1997-2003
28. Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114:38-44 (Pubitemid 351998750)
29. Muller K, Weidinger C, Fuhrer D (2010) Insulin glargine and insulin have identical effects on proliferation and phosphatidylinositol 3-kinase/AKT signalling in rat thyrocytes and human follicular thyroid cancer cells. Diabetologia 53:1001-1003
30. Owens DR, Bolli GB (2008) Beyond the era of NPH insulin-long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther 10:333-349
31. Pollak M (2012) The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 12:159-169
32. Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, Haak HR, Geelhoed-Duijvestijn PH et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55:51-62
33. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S et al (2010) Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling. Diabetologia 53:1743-1753
34. Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429-441
35. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, Kurrle R et al (2010) In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PLoS ONE 5:e9540
36. Staiger K, Hennige AM, Staiger H, Haring HU, Kellerer M (2007) Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res 39:65-67 (Pubitemid 46535160)
37. Swift S, Lorens J, Achacoso P, Nolan GP (2001) Rapid production of retroviruses for efficient gene delivery to mammalian cells using 293T cell-based systems. Curr Protoc Immunol Chapter 10:Unit 10 7C
38. Teng JA, Hou RL, Li DL, Yang RP, Qin J (2011) Glargine promotes proliferation of breast adenocarcinoma cell line MCF-7 via AKT activation. Horm Metab Res 43:519-523
39. Thevis M, Thomas A, Delahaut P, Bosseloir A, Schanzer W (2005) Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal Chem 77:3579-3585 (Pubitemid 40803497)
40. Varewijck AJ, Yki-Jarvinen H, Schmidt R, Tennagels N, Janssen JA (2013) Concentrations of insulin glargine and its metabolites during long-term insulin therapy in Type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGFI, and human insulin on insulin and IGF-I receptor signaling. Diabetes
41. Warnken M, Reitzenstein U, Sommer A, Fuhrmann M, Mayer P, Enzmann H et al (2010) Characterization of proliferative effects of insulin, insulin analogues and insulin-like growth factor-1 (IGF-1) in human lung fibroblasts. Naunyn Schmiedebergs Arch Pharmacol 382:511-524
42. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V et al (2002) A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245-254 (Pubitemid 34084698)
43. Vichai V, Kirtikara K, Sulforhodamine B (2006) Colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116
44. Wada T, Azegami M, Sugiyama M, Tsuneki H, Sasaoka T (2008) Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin. Diabetes Res Clin Pract 81:269-277
45. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2009) Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41-49
46. Yehezkel E, Weinstein D, Simon M, Sarfstein R, Laron Z, Werner H (2010) Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia 53:2667-2675
47. Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J et al (2011) Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3 K/Akt signaling routes. Breast Cancer Res 13:R52